Drug Trial Radar · NCT06234345
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,252
Planned (sponsor's estimate)
Start
Jan 30, 2027
Primary completion
Aug 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Eurofarma Laboratorios S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Several studies have demonstrated the benefits of the LAMA (Long-Acting Muscarinic Antagonists) + LABA (Long-Acting Beta-Agonists) + IC (inhaled corticosteroids) combination in the treatment of chronic obstructive pulmonary disease (COPD). The use of the triple combination in patients with severe airflow obstruction and a history of flares has been associated with improved lung function, improved patient-reported endpoints and prevention of flares, when compared to LABA, LABA + LAMA and LABA + IC. Furthermore, when compared to dual therapies LABA + IC and LABA + LAMA, triple therapy has been able to reduce all-cause deaths among chronic obstructive pulmonary disease (COPD) patients. Previously published studies have demonstrated that the triple combination of Fluticasone 250 mcg/Formoterol 12 mcg/Glycopyrronium 12.5 mcg was able to improve lung function in chronic obstructive pulmonary disease (COPD) patients with a history of flares. There was also a significant improvement in the mMRC (modified-Medical Research Council) which began in the 2nd week of treatment and continued up to week 12. The association was considered safe and well tolerated, with only mild to moderate adverse events recorded in approximately 25% of the subjects treated in the study. Furthermore, bioavailability studies performed with the components of the combination proposed as experimental drug - Fluticasone/Formoterol/Glycopyrronium - indicated that there is no pharmacokinetic interaction between the 3 active ingredients when they were administered concomitantly to healthy individuals under fasting conditions.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcgDrug
Participants randomized to this group will receive 1 capsule per inhalation twice a day
Comparator - Trimbow®Drug
Participants randomized to this group will receive 2 triggering twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change to morning pre-dose FEV1Time frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eurofarma Laboratorios S.A
São Paulo, Padrão, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.